Purple Biotech Ltd Stock Price, News & Analysis

Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2025 financial results and significant clinical progress across its pipeline. The company highlighted positive data from its CAPTN-3 tri-specific antibody platform at EACR 2025, with plans to submit an IND for IM1240 in 2026.

Key clinical achievements include statistically significant Phase 2 results for CM24 in pancreatic cancer, showing up to 78% reduction in death risk and 37.5% ORR in biomarker-selected patients. The company also initiated a Phase 2 study of NT219 in head and neck cancer.

Financial highlights include reduced R&D expenses to $0.6M (down 76.9% YoY), operating loss of $1.2M (down 64.3% YoY), and cash position of $5.6M, providing runway into Q3 2026.

Purple Biotech (NASDAQ/TASE: PPBT) CEO Gil Efron shared significant progress in their clinical pipeline during H1 2025. The company's lead candidate CM24 showed promising Phase 2 results in pancreatic cancer (PDAC), with notably higher objective response rates in biomarker-enriched subgroups (37.5% vs 0% control).

Key developments include positive data from the CAPTN-3 platform presented at EACR 2025, featuring novel capping technology, and advancement of NT219 into Phase 2 combination studies. The company plans to initiate a biomarker-driven Phase 2b study for CM24 and expects to submit an IND for CAPTN-3's first candidate in 2026.

Purple Biotech maintains a cash runway extending into mid-2026, though additional funding will be required for future clinical studies.

Purple Biotech (NASDAQ/TASE: PPBT) presented new preclinical data on its CAPTN-3 tri-specific antibody platform at EACR 2025. The platform creates antibodies that safely activate both innate and adaptive immune systems to fight cancer. The lead product, IM1240, features a conditional anti-CD3 arm that activates only in tumor environments, an anti-NKG2A arm that engages NK cells and blocks immune checkpoints, and a tumor-targeting arm. Key data showed sustained tumor regression in triple negative breast cancer models, selective activation in tumor microenvironment, and synergistic effects between NK and T cell engagement. The platform demonstrated superior efficacy compared to individual antibodies and showed flexibility with other candidates like IM1060 and IM1065 also achieving significant tumor regression.

Purple Biotech (NASDAQ/TASE: PPBT) has initiated a Phase 2 clinical study of NT219 for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study, conducted at the University of Colorado Anschutz Medical Campus, will evaluate NT219 in combination with either pembrolizumab or cetuximab. NT219 is a novel small molecule targeting IRS1/2 and STAT3 pathways. The trial consists of two single-arm cohorts, each starting with 10 patients and potentially expanding to 29 patients. The initiation follows encouraging Phase 1 results showing safety and anti-tumor activity, with two partial responses and five stable disease cases. The SCCHN treatment market is projected to reach $5 billion by 2030.

Purple Biotech (NASDAQ/TASE: PPBT) announced it will present a poster at the European Association for Cancer Research (EACR) 2025 Congress in Lisbon, Portugal from June 16-19, 2025. The presentation will focus on their CAPTN-3 tri-specific antibody platform, a novel technology for conditionally activated T cell and NK cell engagers. Dr. Hadas Reuveni, VP of R&D at Purple Biotech, will present the poster titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers" during the Immunotherapy session on June 17, 2025. The abstract (EACR25-1964) will be published online after the presentation.

Purple Biotech (NASDAQ/TASE: PPBT) reported Q1 2025 financial results and clinical progress. Key highlights include final CM24 Phase 2 data showing significant efficacy in biomarker subgroups, with up to 90% reduction in death risk in specific patient populations. The company plans to initiate a Phase 2b study in H2 2025. NT219's Phase 2 head and neck cancer trial is set to begin in H1 2025, combining with pembrolizumab or cetuximab. The company's CAPTN-3 platform continues advancing toward first-in-human trials. Financial results showed reduced R&D expenses to $0.8M (down 76.5% YoY), operating loss of $1.4M (down 68.9% YoY), and net loss of $0.5M. Cash position stands at $6.7M, providing runway into mid-2026.

Purple Biotech (NASDAQ/TASE: PPBT) has appointed Shai Lankry as its new Chief Financial Officer. Lankry brings over 20 years of financial leadership experience in biotech and healthcare sectors. His notable career includes serving as CFO of Gamida Cell Ltd. (2018-2023), Finance Director at West Pharmaceutical Services (2016-2018), and CFO at MacroCure Ltd. (2013-2017), where he successfully led a U.S. IPO and M&A transaction with Leap Therapeutics.

Most recently, Lankry operated his own consulting firm, LS Consulting Services. He holds an M.B.A. in Finance from Tel-Aviv University and is a licensed Israeli CPA. The appointment comes as Purple Biotech, a clinical-stage company developing first-in-class therapies for tumor immune evasion and drug resistance, advances its pipeline into late-stage trials.

Purple Biotech announced final data from its Phase 2 study of CM24 in pancreatic cancer patients at AACR 2025. The study showed significant efficacy in biomarker-enriched subgroups, with up to 90% reduction in death risk in specific patient populations.

Key findings include:

• 78% reduction in death risk for patients with specific CEACAM1 ranges
• 61% reduction in death risk for patients with defined CEACAM1 or MPO levels
• 90% reduction in death risk for patients with high tumor CEACAM1 and low PD-L1 CPS

The combination therapy of CM24, nivolumab, and chemotherapy was well-tolerated and showed improvements in all efficacy measures. The study identified CEACAM1 as a potential biomarker, both in serum and tumor tissue. Based on these results, Purple Biotech plans to conduct a biomarker-driven Phase 2b study, potentially expanding into gastric and biliary tract cancer treatments.

Purple Biotech (NASDAQ/TASE: PPBT) presented new data for NT219, their dual inhibitor of IRS1/2 and STAT3, at AACR 2025. The company revealed positive findings from two posters focusing on colorectal and head and neck cancers.

Key findings include:

• NT219 shows potential in overcoming immune evasion mechanisms and restoring immunotherapy efficacy in head and neck squamous cell carcinoma (HNSCC)
• Upregulation of pIGF1R and pSTAT3 correlated with patient response, suggesting potential biomarkers
• In colorectal cancer, APC-loss or enhanced wnt/β-catenin signaling may serve as biomarkers for NT219 treatment effectiveness
• The drug demonstrated ability to reverse chemo-resistance and synergize with approved chemotherapy in multiple models